BIOA Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
298.0K
-87.8%
2.5M
-11.6%
2.8M
-9.9%
3.1M
+49.9%
2.1M
Cost of Revenue
0
0
0
0
0
Gross Profit
298.0K
-87.8%
2.5M
-11.6%
2.8M
-9.9%
3.1M
+49.9%
2.1M
Operating Expenses
37.7M
+18.6%
31.8M
+12.9%
28.1M
-10.6%
31.5M
+25.0%
25.2M
R&D
30.2M
+24.1%
24.4M
+19.4%
20.4M
-16.7%
24.5M
+32.3%
18.5M
SG&A
7.5M
+0.8%
7.4M
-4.1%
7.7M
+10.5%
7.0M
+4.8%
6.7M
Operating Income
-37411000
-27.5%
-29333000
-15.6%
-25375000
+10.7%
-28423000
-22.8%
-23140000
EBITDA
-37331000
-27.6%
-29263000
-15.6%
-25312000
+10.7%
-28354000
-22.8%
-23091000
Net Income
-33504000
-28.4%
-26097000
-17.3%
-22253000
+14.2%
-25943000
-28.6%
-20171000
EPS (Basic)
$-0.73
-25.9%
$-0.58
-11.5%
$-0.52
+27.8%
$-0.72
-28.6%
$-0.56
EPS (Diluted)
$-0.73
-25.9%
$-0.58
-11.5%
$-0.52
+27.8%
$-0.72
-28.6%
$-0.56
Shares (Diluted)
45.9M
+2.4%
44.8M
+5.6%
42.5M
+17.4%
36.2M
+0.9%
35.9M
BioAge Labs (BIOA) — Financials